Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al. · Journal of the National Comprehensive Cancer Network · 2017
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
Cited by 1,303 works. doi:10.6004/jnccn.2017.0050
Authors
- David S. Ettinger
- Douglas E. Wood
- Dara L. Aisner
- Wallace Akerley
- Jessica Ruth Bauman
- Lucian R. Chirieac
- Thomas Anthony D’Amico
- Malcolm M. DeCamp
- Thomas J. Dilling
- Michael Christian Dobelbower
- Robert Charles Doebele
- Ramaswamy Govindan
- Matthew A. Gubens
- Mark W. Hennon
- Leora Horn
- Ritsuko R. Komaki
- Rudy P. Lackner
- Michael D. Lanuti
- Ticiana A.B. Leal
- Leah J. Leisch
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- SEER Cancer Statistics Review, 1975-2003
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR